Repligen Announces Identification Of Drug Target For Friedreich's Ataxia
Medical News Today
26 September 2009
Repligen Corporation (Nasdaq: RGEN) reported publication of research that identifies histone deacetylase 3 (HDAC 3) as an important enzyme target for therapeutic intervention in Friedreich's ataxia. These research findings confirm the drug target of the HDAC inhibitors that Repligen is currently developing for the treatment of inherited neurodegenerative diseases such as Friedreich's ataxia. The study entitled "Chemical Probes Identify a Role for Histone Deacetylase 3 in Friedreich's Ataxia Gene Silencing" published today in the journal Chemistry & Biology (volume 16, 980-989, September 25, 2009) was conducted in collaboration with scientists at The Scripps Research Institute.
26 September 2009
Repligen Corporation (Nasdaq: RGEN) reported publication of research that identifies histone deacetylase 3 (HDAC 3) as an important enzyme target for therapeutic intervention in Friedreich's ataxia. These research findings confirm the drug target of the HDAC inhibitors that Repligen is currently developing for the treatment of inherited neurodegenerative diseases such as Friedreich's ataxia. The study entitled "Chemical Probes Identify a Role for Histone Deacetylase 3 in Friedreich's Ataxia Gene Silencing" published today in the journal Chemistry & Biology (volume 16, 980-989, September 25, 2009) was conducted in collaboration with scientists at The Scripps Research Institute.
Latest news:
20th July 2011 -
INTERNATIONAL STUDY OF GENETIC ALZHEIMER’S DISEASE GIVES CLUES TO PRESYMPTOMATIC DETECTION AND PROGRESSION OF THE DISEASE
20th July 2011 -
ALZHEIMER’S ASSOCIATION WELCOMES PRESIDENT NICOLAS SARKOZY TO INTERNATIONAL CONFERENCE
20th July 2011 -
LATE BREAKING RESEARCH RESULTS FROM THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2011
19th July 2011 -
NEW GLOBAL MODEL OF ALZHEIMER’S RISK SUGGESTS A 25 PERCENT REDUCTION IN PRESUMED RISK FACTORS COULD LOWER ALZHEIMER’SCASES BY 3 MILLION WORLDWIDE
18th July 2011 -
ALZHEIMER’S ASSOCIATION® TRIALMATCHTM CONNECTS MORE THAN 2,500 PEOPLE WITH ALZHEIMER’S CLINICAL TRIALS NATIONWIDE
18th July 2011 -
BRAIN INJURY MAY MORE THAN DOUBLE DEMENTIA RISK IN OLDER VETERANS
18th July 2011 -
Women at the Center of the Global Alzheimer’s Epidemic
